Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc. director Duncan Moore reported multiple stock transactions. He sold 11,642 shares of common stock at a weighted average price of $5.205 per share in an open-market trade. Following this sale, he directly owned 1,044,928 shares of ASP Isotopes common stock.
The filing also shows two earlier awards of restricted stock for his service as an independent director: 25,469 shares on November 12, 2025 and 36,548 shares on December 18, 2025, both granted at no cash cost. The sale on April 16, 2026 was executed under a Rule 10b5-1 trading plan adopted on December 31, 2025 and included shares sold to cover income tax liabilities from the vesting of a prior restricted stock award.
ASPI submitted a Form 144 notice regarding the potential sale of 25,469 shares of Common Stock. The shares were acquired as compensation (Restricted Stock Award) on 11/12/2025. The filing is dated 04/16/2026 and lists NASDAQ trading.
ASP Isotopes Inc. reported proposed and recent sales of Common Stock by an affiliate via a Form 144 disclosure. The filing shows a 400,000-share Restricted Stock Award acquired 04/14/2025 and two recent dispositions: 8,438 shares sold on 03/06/2026 for $45,894.28 and 25,000 shares sold on 04/13/2026 for $112,775.00.
The record lists these trades as equity compensation and brokered sales; the filing names Robert Ainscow as the selling contact. Timing and amounts are shown explicitly in the disclosure.
ASPI filed a Form 144 notice reporting proposed sales of Common Stock. The excerpt lists quantities including 231,240 and 23,124 tied to restricted stock awards and a larger figure 125,903,447 in the securities information row with date 04/15/2026.
ASP Isotopes Inc. COO Robert Ainscow reported an open‑market sale of 25,000 shares of common stock on March 6, 2026. The sale was executed at a weighted average price of $4.511 per share, with individual trades ranging from $4.42 to $4.58.
These sales were made under a pre‑arranged Rule 10b5-1 trading plan adopted on December 13, 2024, indicating they were scheduled in advance. Following this transaction, Ainscow directly holds 1,512,817 shares of ASP Isotopes common stock.
ASPI notice of proposed sale under Rule 144. A reporting person indicated a proposed sale of 300,000 shares of Common Stock that were acquired as a Restricted Stock Award on 09/06/2024. The filing also shows 8,438 shares sold in the past three months for $45,894.28. Shares outstanding are listed as 125,903,447 as of 04/13/2026.
ASP Isotopes Inc. provided a broad business and financial update, pairing strong balance sheet growth with long‑term profitability goals. The company reported cash, cash equivalents and marketable securities of $333 million as of December 31, 2025, after raising over $345 million in 2025 through common stock and convertible notes. Product revenue for 2025 was $5.7 million, up 46% from $3.9 million in 2024, while net loss attributable to shareholders widened to $175.1 million from $32.3 million.
Management outlined a long‑term EBITDA target of more than $300 million in 2031 and expects first commercial isotope shipments in 2026 across Silicon‑28, Carbon‑14 and Ytterbium‑176. The Virginia Gas Project’s Phase 1 drilling finished roughly four months early, with nameplate capacity of 2,500 GJ per day of LNG and 58 MCF per day of liquid helium expected in the third quarter of 2026.
ASP Isotopes Inc. files its annual report describing a rapid expansion into advanced isotopes, nuclear fuels, helium and LNG, and construction services. The company began commercial isotope production in Pretoria in 2025 and is targeting initial shipments of enriched C-14, Si-28 and Yb-176 in 2026.
ASP acquired Renergen, gaining South Africa’s only onshore petroleum production right and the Virginia Gas Project, which produces LNG and high‑grade helium. Through subsidiary QLE, it is developing HALEU nuclear fuel and lithium enrichment, backed by a $22.0 million conditional loan and long‑term HALEU supply agreements with TerraPower.
The report details 51% ownership of radiopharmacy PET Labs, the ECNP pharmacy acquisition, early‑stage investments in IsoBio and Opeongo, and a controlling interest in Skyline, adding Hong Kong civil engineering services. ASP plans to separate QLE as a standalone public company via a future listing and equity distribution to existing stockholders.
ASP Isotopes Inc. announced that Executive Chairman and CEO Paul Mann will host a business update conference call and webcast on April 13, 2026, at 8:00 AM ET. Investors and the public can join via toll and toll-free numbers or a live webcast, with a replay available on the company’s website.
The company develops proprietary isotope enrichment technologies, including its Aerodynamic Separation Process and Quantum Enrichment, to supply critical materials for nuclear medicine, advanced semiconductors, and nuclear energy. The announcement also highlights that management may discuss forward-looking statements during the call, which are subject to significant risks and uncertainties.
ASP Isotopes Inc. submitted a Form 12b-25 notification stating it could not file its annual report on Form 10-K for the period ended December 31, 2025 within the prescribed time. The company signed the notice on March 31, 2026 and cites Rule 12b-25 procedures.